News und Analysen

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases

Premier Inc. (NASDAQ: PINC), a healthcare improvement company, has formed a new organization that is focused on optimizing care through clinically led partnerships with large, national employers

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including:

• 
  Credit Suisse 28^th Annual Healthcare Conference

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005841/en/

Vifor Pharma and Evotec SE today announced the

Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 28^th Annual Credit Suisse Healthcare Conference on Wednesday, November 13, 2019, at approximately 10:20 a.m

VCU Health System, a comprehensive Level I trauma center verified in adult, pediatric and burn trauma care located in Richmond, Virginia, is collaborating with Premier Inc. (NASDAQ: PINC), a

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases

Regulatory News:

Vifor Pharma today announced a commercial partnership with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to jointly

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Erweiterung seines QIAseg-NGS-Portfolios bekannt. Das Unternehmen bietet künftig einen eintägigen Workflow für die simultane

The Medicines Company (NASDAQ:MDCO) today announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3

Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 first quarter ended Sept. 30, 2019.

All results presented in the following release reflect those of continuing

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a series of agreements that expand its immuno-oncology assets for future commercialization of novel companion diagnostics for

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, honors National Epilepsy Awareness Month in the United States this November. The company is working to bring

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an expansion of its QIAseq NGS portfolio to offer a one-day workflow for simultaneous preparation of DNA and RNA libraries using

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute eine Reihe von Vereinbarungen bekannt, über die es sein Portfolio an Immuno-Onkologie-Lösungen für die künftige Kommerzialisierung neuer

Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 32-cents per share on the Company’s capital stock, payable on December 2, 2019